What it does

Runs clinical trials of microdosed LSD and other psychedelic-based treatments for depression and related conditions, mainly in New Zealand and Australia.

Psychedelic drug researchHealth care

Blackhawk Growth spun out its psychedelic-medicine subsidiary MindBio Therapeutics by plan of arrangement, distributing one MindBio share per Blackhawk share, with listing on the Canadian Securities Exchange expected on or about 5 May 2023.

Distribution date

5 May 2023

Structure

Spin-off

Parent

Blackhawk Growth

Spin-off ticker

MBIO CN

Listing

Canadian Securities Exchange

Market

Canada

Sector

Health care

Size

micro